drugset / Trial / NCT05307328
SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome
RandomizedCrossoverQuadruple-blindTreatment
Summary
This is a randomized, placebo-controlled, study of SPI-62 in subjects with ACTH-dependent Cushing's syndrome caused by a non-adrenal tumor. Subjects will receive each of the following 2 treatments for 24 weeks: SPI-62 and matching placebo with the option of long-term extension.
Timeline
- Start
- 2022-09-01
- Primary completion
- 2025-08-01
- Completion
- 2025-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | clofutriben | Small molecule | — | Oral |